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INTRODUCTION 
Smoking is probably the single most significant source of toxic chemi-
cal exposure to humans and considered one of the main causes of pre-
ventable disease and premature deaths worldwide. The health conse-
quences and medical costs associated with smoking are staggering.1) Cig-
arette smoking increases the incidence of cardiovascular and cardiopul-
monary diseases.2) In addition to the known harmful effects of smoking, 
smoking causes changes to the body composition regarding low skeletal 
muscle and increased abdominal adiposity. Thus, smoking may cause 
sarcopenia that refers to the loss of skeletal muscle mass and strength, 
leading to the increased risk of fall-related injuries, metabolic impair-
ments, and overall mortality.3) 
Sarcopenia has multiple causes such as intrinsic and extrinsic fac-
tors.4-6) Intrinsic factors include increased insulin resistance, advancing 
age, diabetes, metabolic syndrome,4) hormonal change, loss of repairabil-
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Background: This study investigated whether smoking defined as smoking status and smoking level is associated with sarcopenia after the age of 50 
years by sex using data from the Korea National Health and Nutrition Examination Survey. 
Methods: The total number of subjects in this analysis was 8,622. Participants were queried on smoking status (current, past, never) and smoking level 
(light, ≤11.3 pack-years; medium, >11.3–24.5 pack-years; heavy, >24.5 pack-years). Sarcopenia was evaluated by dividing the body weight by the 
appendicular skeletal muscle mass (ASM/Wt). Logistic regression analysis was performed to examine the association between sarcopenia and 
smoking, after adjusting for potential confounders.
Results: Smoking status was not associated with sarcopenia in men and women, but smoking level and sarcopenia were significantly related in women. 
After adjusting for confounding factors, the multivariate-adjusted odds ratio (95% confidence interval) of sarcopenia in smokers was 0.383 (0.153–
0.964) in the medium smoking group of women, and 3.456 (1.542–7.742) and 3.052 (1.292–7.207) in the heavy smoking group of women.
Conclusion: Therefore, our study identified smoking as a reversible and independent risk factor for sarcopenia and smoking defined by smoking level 
such as pack-years might be an appropriate definition from a sarcopenia perspective.
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ity, and reduced number of motor units;5) extrinsic factors include mal-
nutrition, alcohol consumption, reduced physical activity, and smoking.6) 
Some cohort studies have identified smoking as a reversible risk factor for 
sarcopenia.7) A previous study has reported that older smokers had lower 
relative lean mass when compared with subjects who had never smoked, 
suggesting that smoking may increase the risk of sarcopenia by promot-
ing muscle wasting and accelerating the decline in physical functioning.8) 
The strategies that delay or prevent the onset of sarcopenia are likely to 
have major consequences for public health.9) Thus, an understanding of 
smoking as a risk factor for sarcopenia could help in the design of preven-
tive interventions, which is of considerable importance for healthy aging.
In a meta-analysis of individual studies about the relation between cig-
arette smoking and sarcopenia, the resulting overall odds ratio (OR) of 
the association between smoking and sarcopenia was 1.12 (95% confi-
dence interval [CI], 1.03–1.21), indicating that smoking as an isolated risk 
factor may contribute to the development of sarcopenia.10) However, the 
results of individual studies were largely inconsistent. In a previous study, 
the estimation of men was significantly below OR=1,11) whereas, the esti-
mate of another study of men was significantly above OR=1.12) This 
could be influenced by the design of the study; smoking was not the 
main topic and the different approaches to measuring the main variables 
including sarcopenia and smoking affected the results.
In the case of smoking status, nearly every study involved in this meta-
analysis was based on the subjective evaluation of participants. A uni-
form assessment method of smoking status was not used, even though a 
method of smoking level was developed, such as pack-years regarding the 
period and quantity of smoking, so, the assignment to categories of 
smokers and non-smokers could not be as objective as in the case of sar-
copenia categories.10) In the aging process, declining sex hormone levels 
in adults over 50 years of age begin to expedite the changes in body com-
position by gender.11) We examined the relationship between smoking 
status and smoking level (pack-years) and sarcopenia among individuals 
aged 50 years or older by sex, who participated in the Korea National 
Health and Nutrition Examination Survey (KNHANES).
METHODS
1. Study Population 
This study extracted participant results from the KNHANES from the 
year 2008 to 2011. The KNHANES is composed of a health interview 
survey, a health examination survey, and a nutrition survey conducted by 
trained investigators. The KNHANES employed a rolling sampling de-
sign that implemented a complex, stratified, multistage probability-clus-
ter survey of a representative Korean population sample.13) Of the 37,753 
participants from the KNHANES of 2008–2011, we initially selected 
those over 50 years of age, and then excluded participants who had any 
malignancy, whose data for variables included in the analysis were miss-
ing, or who were pregnant. The total number of participants in this anal-
ysis was 8,622 (3,696 men and 4,926 women) among those who partici-
pated in the survey between January 2008 and August 2011. The present 
study used data from the KNHANES-V, which re ceived institutional re-
view board approval Pukyong National University (IRB no. 2008-04 
EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-
06-C).
2. Measurements
1) Smoking
Participants were categorized on smoking status. According to the 
self-report response, participants indicated whether they were never 
smokers, past smokers, or current smokers. Past smokers were defined as 
individuals who had smoked in the past, but no longer smoked and cur-
rent smokers were individuals who reported smoking at the survey. Nev-
er smokers were individuals who reported never having a cigarette or 
<100 cigarettes in their lifetime. Participants who were current or past 
smokers were asked about the number of cigarettes smoked per day, the 
age of smoking onset, and if quit, the total number of years of smoking. 
Pack-years, a measure of smoking exposure that takes into account both 
the amount and duration of smoking, was calculated by multiplying the 
number of packs smoked per day by the number of years a person has 
smoked. We grouped the pack-year data for smokers into quartile: light 
smoking (≤11.3 pack-years), medium smoking (>11.3–24.5 pack-years), or 
heavy smoking (>24.5 pack-years).14)
2) Sarcopenia
Appendicular skeletal muscle mass (ASM) was measured by dual-en-
ergy X-ray absorptiometry (Discovery-W; Hologic, Inc., Bedford, MA, 
USA). ASM (kg) was defined as the sum of the lean soft tissue masses of 
the arms and legs.15) Sarcopenia was defined as an ASM/Wt (%) that was 
less than 1 standard deviation below the mean of a sample of healthy 
adults aged 20 to 39 years.3) The reference group of this study included 
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4,987 healthy adults without any history of chronic diseases such as dia-
betes, stroke, coronary artery disease, thyroid disease, arthritis, tubercu-
losis, asthma, chronic obstructive lung disease, liver cirrhosis, and can-
cer.16) The cutoff value for sarcopenia was 23.8% (ASM/Wt) for women 
and 30.3% (ASM/Wt) for men, defined as less than 1 standard deviation 
below the sex-specific normal mean for the reference group in this study.
3) Covariates
Covariates consisted of age, family structure, education, income, job, 
drinking, physical activity, total energy, protein, fat, blood pressure, fast-
ing glucose level, triglyceride level, high-density lipoprotein (HDL)-cho-
lesterol level, and waist circumference. Family structure was categorized 
as living alone or living with another family member. Education level was 
divided into 2 categories as ≤middle school or ≥high school. Monthly in-
come was divided into quartiles according to the equivalent household 
income, as low, medium, or high. Drinking was classified according to 
the reported amount of drinks consumed on average per week or month: 
≥a times/week, 1–4 times/month, or <1 time/month.17) Physical activity 
was assessed using the International Physical Activity Questionnaire.18) 
The subjects were categorized into low, medium and high levels of physi-
cal activity based on their total physical activity (metabolic equivalent 
task min/week) and the frequency of the activities. Dietary intake such as 
total energy, protein and fat were measured by the single 24-hour dietary 
recall method. Among metabolic risk factors, based on the National 
Cholesterol Education Program Adult Treatment Panel III guidelines, 
high blood pressure levels referred to values of more than 130 mmHg of 
systolic blood pressure or 85 mmHg diastolic blood pressure, or taking 
anti-hypertensive medication. High fasting glucose levels were more than 
100 mg/dL or taking a hypoglycemic agent or insulin therapy. High tri-
glyceride levels were more than 150 mg/dL or taking medication for dys-
lipidemia treatment. An HDL-cholesterol level of less than 40 mg/dL for 
men and 50 mg/dL for women, or taking medication for dyslipidemia 
treatment was considered high. High waist circumference was more than 
90 cm for men and 80 cm for women.19) 
3. Statistical Analysis 
All sampling and weight variables were stratified, and the statistical 
analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, 
NY, USA) to account for the complex sampling design. In order to calcu-
late the total population that the sample would represent, we employed 
the stratification variables and sampling weights designated by the Korea 
Centers for Disease Control and Prevention. All data were described as 
unweighted frequencies, weighted percentages, means, and standard de-
viations. Subjects’ characteristics were compared according to the pres-
ence or absence of sarcopenia, using the t-test or chi-square test for cate-
gorical variables and the generalized linear model for continuous vari-
ables. Multiple logistic regression analyses were used to determine the as-
sociation between sarcopenia and smoking. 
RESULTS
1. Characteristics of the Study Subjects by Sex
The general characteristics of the subjects are shown in Table 1. 
Among the men, the percentage of past smokers was higher in sarcope-
nia than non-sarcopenia. Among the women, the number of heavy level 
smokers was higher in sarcopenia than non-sarcopenia. Also, subjects 
with sarcopenia had lower protein intake amounts. In both sexes, age, 
job, physical activity, total energy, blood pressure, fasting glucose, triglyc-
eride, HDL-cholesterol and waist circumference demonstrated statisti-
cally significant differences according to the presence or absence of sar-
copenia. Subjects with sarcopenia were older and were unemployed. The 
levels of blood pressure, fasting glucose, triglycerides, and waist circum-
ference were significantly higher in sarcopenia than non-sarcopenia. 
Also, HDL-cholesterol levels were lower in subjects with sarcopenia. The 
prevalence of sarcopenia was 36.0% among men and 37.8% among wom-
en.
2. Association between Smoking Status and Sarcopenia 
To identify the association between smoking status and sarcopenia, 
multiple logistic regression analysis was performed (Table 2). Among the 
men, after adjustment for age, family structure, education, income, job, 
drinking, physical activity, total energy, protein and fat (model 1), the 
ORs for sarcopenia were 1.222 (95% CI, 0.924–1.615) in the past smoking 
group and 0.924 (95% CI, 0.695–1.227) in the current smoking group 
compared with the never smoking group. Controlling further for blood 
pressure, fasting glucose, triglyceride, HDL-cholesterol, and waist cir-
cumference (model 2), the ORs for sarcopenia were 1.218 (95% CI, 0.901–
1.648) in the past smoking group and 0.976 (95% CI, 0.711–1.340) in the 
current smoking group compared with the never smoking group. 
Among women, after adjustment for age, family structure, education, in-
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Table 1. Characteristics of subjects according to sarcopenia by sex (n=8,622)
Characteristics Categories
Men (n=3,696) Women (n=4,926)
Sarcopenia (-) Sarcopenia (+) P-value Sarcopenia (-) Sarcopenia (+) P-value
Age (y) 59.91±0.38 63.04±0.32 <0.001 62.75±0.37 63.57±0.28 0.025
Family structure Single 118 (4.2) 80 (5.3) 0.163 469 (12.2) 299 (13.2) 0.384
With family 2,227 (95.8) 1,265 (94.7) 2,583 (87.8) 1,567 (86.8)
Education ≤Middle 1,332 (54.0) 751 (54.7) 0.758 2,396 (77.8) 1,502 (80.5) 0.083
≥High 993 (46.0) 581 (45.3) 621 (22.2) 342 (19.5)
Income Low 662 (23.7) 409 (26.4) 0.119 1,111 (33.4) 676 (34.5) 0.712
Medium 1,108 (48.7) 637 (49.4) 1,337 (46.7) 830 (46.6)
High 547 (27.6) 283 (24.2) 557 (19.9) 333 (18.8)
Job No 638 (24.6) 574 (37.0) <0.001 1,653 (55.1) 1,167 (61.2) 0.001
Yes 1,686 (75.4) 759 (63.0) 1,365 (44.9) 677 (38.8)
Smoking status Never 435 (18.4) 243 (17.6) <0.001 2,771 (90.9) 1,716 (92.4) 0.232
Past 1,028 (41.7) 715 (50.2) 94 (3.6) 61 (3.5)
Current 862 (39.9) 380 (32.2) 151 (5.5) 67 (4.1)
Smoking level* Light 389 (20.5) 236 (20.3) 0.778 149 (62.0) 66 (55.2) 0.004
Medium 473 (25.5) 268 (24.3) 69 (27.7) 26 (18.3)
Heavy 1,023 (54.0) 585 (55.5) 27 (10.4) 36 (26.5)
Drinking (times) ≥2/wk 1,021 (44.4) 504 (40.8) 0.018 197 (7.0) 96 (5.8) 0.088
1–4/mo 619 (27.8) 345 (26.4) 582 (21.1) 336 (18.7)
<1/mo 684 (27.8) 483 (32.8) 2,237 (71.9) 1,403 (75.5)
Physical activity Low 740 (32.4) 528 (41.0) <0.001 1,207 (40.0) 866 (46.9) <0.001
Medium 709 (30.5) 477 (33.3) 1,015 (33.5) 620 (34.3)
High 875 (37.1) 330 (25.7) 795 (26.5) 358 (18.8)
Total energy (kcal/day) 2,214.87±35.51 2,054.79±29.75 <0.001 1,579.29±23.92 1,502.72±18.34 0.001
Protein (g/day) 77.16±1.68 72.16±1.32 0.003 52.30±1.03 51.23±0.83 0.302
Fat (g/day) 36.10±1.38 35.41±1.17 0.617 22.58±0.72 22.71±0.59 0.858
Blood pressure (mmHg) High 1,345 (55.9) 984 (72.4) <0.001 1,745 (55.4) 1,311 (69.0) <0.001
Low 1,000 (44.1) 365 (27.6) 1,313 (44.6) 557 (31.0)
Fasting glucose (mg/dL) High 957 (41.4) 736 (57.4) <0.001 946 (33.7) 772 (44.8) <0.001
Low 1,325 (58.6) 545 (42.6) 1,947 (66.3) 972 (55.2)
Triglyceride (mg/dL) High 823 (37.9) 647 (53.7) <0.001 1,006 (35.1) 832 (46.3) <0.001
Low 1,457 (62.1) 628 (46.3) 1,886 (64.9) 914 (53.7)
HDL-cholesterol (mg/dL) Low 523 (24.0) 493 (37.7) <0.001 1,418 (47.8) 972 (53.3) 0.003
High 1,757 (76.0) 782 (62.3) 1,474 (52.2) 774 (46.7)
Waist circumstance (cm) High 443 (19.3) 663 (51.4) <0.001 1,489 (48.9) 1,473 (79.2) <0.001
Low 1,896 (80.7) 684 (48.6) 1,559 (51.1) 388 (20.8)
Prevalence of sarcopenia (%) 36.0 37.8
Values are presented as mean±standard deviation or number (weighted %).
HDL, high-density lipoprotein.
*Smoking level was divided into pack-year of smoking ([packs smoked per day]×[years as a smoker]; light ≤11.3; medium >11.3–24.5; heavy >24.5). 
P-values were calculated by t-test or chi-square test.
Table 2. Association between smoking status and sarcopenia
Smoking status
Never Past Current
Reference OR (95% CI) P-value OR (95% CI) P-value
Men
   Model 1 1 1.222 (0.924–1.615) 0.159 0.924 (0.695–1.227) 0.582
   Model 2 1 1.218 (0.901–1.648) 0.200 0.976 (0.711–1.340) 0.881
Women
   Model 1 1 0.808 (0.518–1.260) 0.345 0.677 (0.450–1.020) 0.062
   Model 2 1 0.840 (0.524–1.345) 0.467 0.811 (0.523–1.259) 0.350
Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by logistic regression analysis. 
Model 1 was adjusted for age, family structure, education, income, job, drinking, physical activity, total energy, protein and fat; Model 2 was adjusted for all variables in 
model 1 plus blood pressure, fasting glucose, triglyceride, high density lipoprotein-cholesterol and waist circumstance. 
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come, job, drinking, physical activity, total energy, protein and fat (model 
1), the ORs for sarcopenia were 0.808 (95% CI, 0.518–1.260) in the past 
smoking group and 0.677 (95% CI, 0.450–1.020) in the current smoking 
group compared with the never smoking group. Further adjustment for 
blood pressure, fasting glucose, triglyceride, HDL-cholesterol and waist 
circumference (model 2), the ORs for sarcopenia were 0.840 (95% CI, 
0.524–1.345) in the past smoking group and 0.811 (95% CI, 0.523–1.259) 
in the current smoking group compared with the never smoking group. 
There was no statistical significance according to the smoking status in 
both sexes.
3. Association between Smoking Level and Sarcopenia 
To determine the association between smoking level and sarcopenia, 
multiple logistic regression analysis was performed (Table 3). Among the 
men, after adjustment for age, family structure, education, income, job, 
drinking, physical activity, total energy, protein and fat (model 1), the OR 
for sarcopenia was 0.972 (95% CI, 0.725–1.253) in the heavy level of 
smoking group compared with the light level of smoking group and was 
not statistically significant. Controlling further for blood pressure, fast-
ing glucose, triglyceride, HDL-cholesterol and waist circumference 
(model 2), the OR for sarcopenia was 0.951 (95% CI, 0.722–1.253) in the 
heavy level of smoking group compared with the light level of smoking 
group and was not statistically significant. However, among women, 
compared with the light level of smoking group, the ORs for sarcopenia 
were 0.383 (95% CI, 0.153–0.964) in the medium level of smoking group 
and 3.456 (95% CI, 1.542–7.742) in the heavy level of smoking group, con-
trolling for age, family structure, education, income, job, drinking, physi-
cal activity, total energy, protein, and fat. Both smoking groups were sta-
tistically significant (model 1). After further adjustment for blood pres-
sure, fasting glucose, triglyceride, HDL-cholesterol, and waist circumfer-
ence (model 2), the OR for sarcopenia was 3.052 (95% CI, 1.292–7.207) in 
the heavy level of smoking group compared with the light level of smok-
ing group and was statistically significant.
DISCUSSION 
The results of this study demonstrated that the prevalence of sarcope-
nia was 36.0% for men and 37.8% for women older than 50 years defined 
by only muscle mass of ASM/weight among Koreans. One previous 
study which used other criteria for sarcopenia defined by muscle mass, 
muscle strength, and physical performance in middle-aged and elderly 
Europeans reported that the prevalence of sarcopenia was 11.9% among 
men.20) The difference in prevalence of sarcopenia is probably due to the 
lack of consensus regarding the optimal approach for diagnosis. Some 
initiatives have been undertaken to find consensus on a standardized 
definition of sarcopenia.21) It appeared to be insufficient to diagnose sar-
copenia by measuring only muscle mass. Therefore, two consensus defi-
nitions were suggested, including loss of muscle function or muscle 
strength and physical performance in its definition.21) According to the 
definition used, prevalence rate estimates of sarcopenia among people 
aged 60 years and older can vary between 3% and 52%.22,23) Early identifi-
cation of sarcopenia would be of great clinical relevance because the loss 
of muscle mass and strength with aging can be largely reversed by proper 
exercise and nutritional intervention.24,25) For adequate identification of 
sarcopenia, it is necessary to apply the proper definition of sarcopenia 
considering muscle mass, strength, and physical performance.
We found that the association of smoking level with sarcopenia was 
significant; after adjusting for confounding factors in women, the dose-
Table 3. Association between smoking level and sarcopenia
Smoking level*
Light Medium Heavy
Reference OR (95% CI) P-value OR (95% CI) P-value
Men
   Model 1 1 1.018 (0.771–1.344) 0.897 0.972 (0.725–1.253) 0.469
   Model 2 1 1.097 (0.853–1.411) 0.847 0.951 (0.722–1.253) 0.719
Women  
   Model 1 1 0.383 (0.153–0.964) 0.042 3.456 (1.542–7.742) 0.003
   Model 2 1 0.464 (0.168–1.285) 0.139 3.052 (1.292–7.207) 0.011
Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by logistic regression analysis.
Model 1 was adjusted for age, family structure, education, income, job, drinking, physical activity, total energy, protein and fat; Model 2 was adjusted for all variables in 
model 1 plus blood pressure, fasting glucose, triglyceride, high density lipoprotein-cholesterol and waist circumstance. 
*Pack-year of smoking=(packs smoked per day)×(years as a smoker); reference: Light ≤11.3; Medium >11.3–24.5; Heavy >24.5. 
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response relationship for smoking and sarcopenia was stronger in wom-
en than in men in this study. This is in line with previous study reporting 
an association between smoking and the age-related loss of muscle 
mass.7) In this cohort study conducted to investigate risk factors for sar-
copenia, it has been shown that smokers had lower appendicular skeletal 
muscle mass than did subjects who never smoked, and among the smok-
ers, appendicular skeletal muscle mass values were lower in those who 
smoked more. 
Recently, according to the model of accelerated muscle loss by smok-
ing, potential metabolites of smoking such as aldehydes and reactive oxy-
gen species that are assumed to be important in this process, enter the 
bloodstream and reach the skeletal muscles of smokers and accelerate 
muscle wasting by increasing oxidative stress, promoting muscle catabol-
ic processes, and inhibiting anabolism.9) Also, smoking can affect sys-
temic processes leading to increased inflammatory activity, insulin resis-
tance, and metabolism. These may also affect skeletal muscle, providing 
a possible physiological explanation for the catabolic effects of smok-
ing.26,27) Another study revealed that smoking increased the risk of sarco-
penia by impairing synthesis of muscle protein and increasing the ex-
pression of genes associated with impaired muscle maintenance.28) In 
general, health risk behaviors such as low levels of physical activity and 
poor nutrition intake have a significant influence on sarcopenia and 
smoking is known to be associated with physical inactivity and malnutri-
tion.29) Our study identified smoking as an independent reversible risk 
factor for sarcopenia. Identification of the association between smoking 
and sarcopenia may help in developing strategies to prevent and delay the 
progress of sarcopenia for health promotion among smokers. 
In this study, smoking status was not associated with sarcopenia in 
both sexes. However, another Korean study reported that smoking sig-
nificantly decreases the risk of sarcopenia in men.11) These differences 
might be partially explained by the design of the study, where smoking 
was not the main topic, unlike this study and sexual characteristics. Of 
note, smoking defined by smoking level was more closely associated with 
sarcopenia than that defined by smoking status in women. Sarcopenia 
refers to the gradual decline in muscle mass and quality noted with ad-
vancing age, which includes the concept of time.6) In this study, the 
smoking level considering the amount and duration of smoking was 
more significant than the smoking status by the cross-sectional question-
naire. However, smoking level was not associated with sarcopenia in 
men. This seems to require more research on the relation between smok-
ing and sarcopenia with more properly designed studies. This result sug-
gests that smoking defined by smoking level might be an appropriate 
definition from a sarcopenia perspective.
The present study has several strengths. Our study identified smoking 
as the main topic for risk factors of sarcopenia using a representative na-
tionwide survey. Furthermore, the pack-years method of assessing smok-
ing designed by the World Health Organization10) was used for evaluat-
ing smoking level. However, this study has several limitations. First, a 
cross-sectional study design precludes our ability to determine a causal 
relationship between smoking and sarcopenia. Also, we did not evaluate 
individual muscle strengths or physical performance in assessing sarco-
penia. 
Smoking is independently associated with sarcopenia in Korean 
women older than 50 years. Smoking defined by smoking level such as 
pack-years might be better for predicting the association with sarcopenia 
than that defined by smoking status in women. It is necessary to develop 
the health promotion program for assessing the high-risk group of sarco-
penia by smoking level among smokers and apply smoking cessation 
counseling to them. In addition, longitudinal studies are warranted to 
investigate the role of smoking based on this definition such as pack-
years in predicting sarcopenia.
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